Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer

摘要: The role of PD-L1 as a prognostic and predictive biomarker is an area great interest. However, there lack consensus on how to deliver clinical biomarker. At the heart this conundrum subjective scoring IHC in most studies date. Current standard systems involve separation epithelial inflammatory cells find significance different percentages expression, e.g., above or below 1%. Clearly, objective, reproducible accurate approach would bring degree necessary consistency landscape. Using systematic comparison technologies application QuPath, digital pathology platform, we show that high expression associated with improved outcome Triple Negative breast cancer context care (SoC) chemotherapy, consistent previous findings. In addition, demonstrate for first time also better ER- disease whole including HER2+ cancer. We influence antibody choice quantification impact Ventana (SP142) providing robust assay our hands. Through sampling regions tumour, tumour rich display greatest range has compared stroma lymphoid areas. Furthermore, observe both are survival chemotherapy. Moreover, seen inhibitor studies, low threshold stratifies patient outcome. This emphasises importance using precise quantitation achieve scores can discriminate expression.